BCR and prostate adenocarcinoma: We further attempted to identify subgroups of PRAD patients who bore a specific profile (i.e., overlapping unfavorable expression profiles of particular predictors significantly differentiating BCR-free survival) corresponding to worse clinical outcomes that increased the molecular potential for PRAD recurrence.